The author defends
‘How many people know that eight patients in Hyderabad who were administered recombinant streptokinase to test its efficacy and safety have died? According to the Genetic Engineering Approval Committee (GEAC), the trial was being conducted by the drug’s manufacturer Shantha Biotechnics without taking clearance. Not surprisingly, the Company denies the allegation claiming that it had taken permission from the DCGI.
There are currently no refbacks.